The purpose of this Core is to provide molecular biological and FIV-related cell culture support for he overall program. The Core will prepare, over-express, purify, and test all proteases to be employed in studies by the investigators of the Program Project. Constructs will include wild type ind drug-resistant proteases from HIV-1 and FIV, as well as a discrete set of tethered dimers that ire hybrids between wild type and drug-resistant proteases. The constructs will be prepared in E. :oh and re-folded by procedures well established in our laboratory. Construct proteases will be monitored for catalytic efficiency, using either fluorigenic substrates at our disposal or by HPLC analysis, where required. Bacterial, insect, and mammalian cell expression systems are also maintained to facilitate over-expression of natural substrates, where required. The Core will also test he efficacy of compounds developed by the Program for ability to inhibit FIV expression in tissue culture. Results may then be compared to efficacy against HIV-1 expression ex vivo, to be carried out by the Torbett laboratory.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Program Projects (P01)
Project #
2P01GM048870-11
Application #
6553747
Study Section
Special Emphasis Panel (ZRG1)
Project Start
1992-09-30
Project End
2007-08-31
Budget Start
Budget End
Support Year
11
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Scripps Research Institute
Department
Type
DUNS #
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Morris, Garrett M; Green, Luke G; Radi?, Zoran et al. (2013) Automated docking with protein flexibility in the design of femtomolar ""click chemistry"" inhibitors of acetylcholinesterase. J Chem Inf Model 53:898-906
Breuer, Sebastian; Sepulveda, Homero; Chen, Yu et al. (2011) A cleavage enzyme-cytometric bead array provides biochemical profiling of resistance mutations in HIV-1 Gag and protease. Biochemistry 50:4371-81
Chang, Max W; Torbett, Bruce E (2011) Accessory mutations maintain stability in drug-resistant HIV-1 protease. J Mol Biol 410:756-60
Chang, Max W; Giffin, Michael J; Muller, Rolf et al. (2010) Identification of broad-based HIV-1 protease inhibitors from combinatorial libraries. Biochem J 429:527-32
Chang, Max W; Ayeni, Christian; Breuer, Sebastian et al. (2010) Virtual screening for HIV protease inhibitors: a comparison of AutoDock 4 and Vina. PLoS One 5:e11955
Sundstrom, Magnus; Chatterji, Udayan; Schaffer, Lana et al. (2008) Feline immunodeficiency virus OrfA alters gene expression of splicing factors and proteasome-ubiquitination proteins. Virology 371:394-404
Nelson, Josh D; Kinkead, Heather; Brunel, Florence M et al. (2008) Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics. Virology 377:170-83
Giffin, Michael J; Heaslet, Holly; Brik, Ashraf et al. (2008) A copper(I)-catalyzed 1,2,3-triazole azide-alkyne click compound is a potent inhibitor of a multidrug-resistant HIV-1 protease variant. J Med Chem 51:6263-70
Huey, Ruth; Morris, Garrett M; Olson, Arthur J et al. (2007) A semiempirical free energy force field with charge-based desolvation. J Comput Chem 28:1145-52
Heaslet, Holly; Rosenfeld, Robin; Giffin, Mike et al. (2007) Conformational flexibility in the flap domains of ligand-free HIV protease. Acta Crystallogr D Biol Crystallogr 63:866-75

Showing the most recent 10 out of 60 publications